CAH
Cardinal Health, Inc.
CAH's fundamentals are mixed: revenue grew 10%, while its operating margin held steady at 1%. At 36x earnings, it's trading above its usual 30x. Analysts expect strong earnings growth.
CAH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
CAH's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
CAH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $130 | -53% |
| Forward | 21x | $278 | — |
| Fair | 30x | $231 | -17% |
| Current | 36x | $278 | — |
| Expensive | 44x | $341 | +23% |
Historical ranges are pointers, not guarantees.
CAH's PE is in its expensive range at 36x. If earnings grow as analysts expect, today's price would be 21x next year's earnings, in its cheap range.
CAH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect CAH's earnings to grow, with its revenue and profitability holding steady.
CAH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.11 | +70% |
| Q3 2026 | $7.73 | +17% |
| Q2 2026 | $7.23 | +12% |
| Q1 2026 | $6.54 | +2.5% |
| Q4 2025 | $6.95 | +30% |
| Q3 2025 | $6.63 | +30% |
| Q2 2025 | $6.45 | +88% |
| Q1 2025 | $6.38 | +182% |
| Q4 2024 | $5.33 | +109% |
CAH's earnings per share have climbed steadily: $7.73 over the past year, up 17% from the year before, and higher year over year for 15 quarters in a row.
CAH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $67.5B | +5.5% |
| Q2 2026 | $63.7B | +5.8% |
| Q1 2026 | $60.9B | +11% |
| Q4 2025 | $65.6B | +19% |
| Q3 2025 | $64B | +22% |
| Q2 2025 | $60.2B | +0.8% |
| Q1 2025 | $54.9B | -0.1% |
| Q4 2024 | $55.3B | -3.8% |
CAH's revenue has grown year over year for six quarters in a row: $67.5B last quarter, up 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.1% | +0.1 points |
| Q2 2026 | 1.1% | +0.4 points |
| Q1 2026 | 0.8% | -0.5 points |
| Q4 2025 | 1.1% | +0.1 points |
| Q3 2025 | 1% | -0.1 points |
| Q2 2025 | 0.7% | 0 points |
| Q1 2025 | 1.3% | +0.7 points |
| Q4 2024 | 1% | +0.2 points |
CAH's operating margin was 1.1% last quarter, about level with the same quarter a year ago.
CAH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +43% |
| Q2 2026 | $1.4B | +10% |
| Q1 2026 | $1.7B | -40% |
| Q4 2025 | $555M | +$1.1B |
| Q3 2025 | $865M | +$2.6B |
| Q2 2025 | $1.3B | -31% |
| Q1 2025 | $2.8B | +$3B |
| Q4 2024 | -$499M | -146% |
CAH generated $4.9B in free cash flow over the past year, up 10% from the year before.
CAH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -4M shares |
| 1 year | -2.5% | -6M shares |
| 3 years | -6.8% | -17M shares |
| 5 years | -19% | -56M shares |
| Available history | -21% | -61M shares |
CAH has 233M diluted shares, down 2.5% from a year ago, with $1.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | $350M |
| Q1 2026 | $250M |
| Q4 2025 | $383M |
| Q3 2025 | $375M |
| Q2 2025 | — |
| Q1 2025 | $375M |
| Q4 2024 | $15M |
CAH spent $1.5B buying back its own shares over the past year, up 94% from the year before.
CAH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.0x | Very low |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
CAH's net debt is about a year of its operating earnings (EBITDA), down from 1.4 years a year ago.
CAH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 81.9 | Overbought |
CAH's weekly RSI is 71 (overbought) and its Stochastic is 82 (overbought).
CAH PE vs Healthcare Sector
| Metric | CAH | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 39% above |
| PE % | 73 | 29 | 44 pts above |
CAH is trading at 36x earnings, a 39% premium to the Healthcare sector's median of 26x.
CAH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $248.8 | 12% above |
| 20 week MA | $239.7 | 16% above |
| 50 week MA | $222.0 | 25% above |
| 100 week MA | $185.9 | 50% above |
| 200 week MA | $141.9 | 96% above |
CAH is in an uptrend: it's above all five of its weekly moving averages, and 96% above its 200-week average.
CAH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.5 | $53.8 | +4.5% |
| 2021 | $53.8 | $50.8 | -5.7% |
| 2022 | $50.8 | $80.1 | +58% |
| 2023 | $80.1 | $100.8 | +26% |
| 2024 | $100.8 | $119.1 | +18% |
| 2025 | $119.1 | $208.3 | +75% |
| 2026 YTD | $208.3 | $278.1 | +34% |
CAH has finished higher in five of the last six years, two of them by more than 50%. It's up 34% so far in 2026.